Bay­er poach­es newest ear­ly R&D head from Roche; Glax­o­SmithK­line earns ex­pand­ed nod for Shin­grix

Bay­er has plucked its new head of re­search and ear­ly de­vel­op­ment from Roche’s pRED or­ga­ni­za­tion, where he was do­ing much the same thing be­fore mak­ing the leap.

The Ger­man phar­ma com­pa­ny an­nounced this morn­ing that it had signed up Do­minik Ruet­tinger for the post. Be­fore Roche, Ruet­tinger had worked on the Mi­cromet team, which put him on Blin­cy­to, a pi­o­neer­ing bis­pe­cif­ic ap­proved in 2014.

“We are pleased to wel­come Do­minik Ruet­tinger who is a leader in on­col­o­gy trans­la­tion­al clin­i­cal re­search and ther­a­peu­tic de­vel­op­ment and brings ex­ten­sive ex­pe­ri­ence that will help us to lever­age sci­ence and in­no­v­a­tive so­lu­tions to change med­ical prac­tice and ul­ti­mate­ly cre­ate su­pe­ri­or out­comes for can­cer pa­tients,” said Chris­t­ian Rom­mel, who heads up R&D at Bay­er. — John Car­roll

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER